22 results
DEF 14A
NAMS
NewAmsterdam Pharma Company NV
9 May 24
Definitive proxy
4:15pm
($)
Bonus ($)
Option Awards
($) (1)
Total ($)
Michael Davidson, M.D.
Chief Executive Officer (2)
John Kastelein, M.D., Ph.D. FESC
Chief Scientific … for such service.
Dr. Kastelein is paid his salary and bonus in Euros. The table above presents Dr. Kastelein’s compensation converted into USD at a rate
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
-based compensation expenses, bonus plans and payments to contractors who work for us for a fixed number of hours per week or per month;
preclinical
PRE 14A
NAMS
NewAmsterdam Pharma Company NV
29 Apr 24
Preliminary proxy
5:00pm
compensation awarded to or earned by our named executive officers.
Name and Principal Position
Year
Salary ($)
Bonus ($)
Option Awards
($) (1)
Total … and bonus in Euros. The table above presents Dr. Kastelein’s compensation converted into USD at a rate of $1.0812 per Euro, which was the average
10-K
2023 FY
EX-10.9
NAMS
NewAmsterdam Pharma Company NV
28 Feb 24
Annual report
8:00am
will be eligible to receive an annual performance bonus targeted at 45% of your Base Salary. Any bonus awarded for the calendar year in which your … employment commences will be prorated based on the Effective Date. The actual bonus amount, whether a bonus is paid, and the amount of any bonus
10-K
2023 FY
NAMS
NewAmsterdam Pharma Company NV
28 Feb 24
Annual report
8:00am
for growth, success and professional development. We provide a competitive compensation and benefits package, including bonus and equity incentive plans … compensation expenses, bonus plans and payments to contractors who work for us for a fixed number of hours per week or per month;
preclinical
10-K
EX-10.8
nokoamj3g tilvz2n
28 Feb 24
Annual report
8:00am
10-K
EX-10.7
v7zii09t
28 Feb 24
Annual report
8:00am
10-K
EX-97.1
vh00s1ry
28 Feb 24
Annual report
8:00am
8-K
EX-1.1
6x2y6f
15 Feb 24
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
4:18pm
F-3
EX-1.2
nytoij4c4ijv4y9ym
7 Dec 23
Shelf registration (foreign)
4:16pm
424B3
qx1fe 4xwg2fu
15 Aug 23
Prospectus supplement
4:52pm
POS AM
13gq2ch6thepfisk 9g
7 Aug 23
Prospectus update (post-effective amendment)
7:56am
6-K
EX-99.2
fp6fppuu0up
7 Aug 23
Research and development expenses
7:24am
424B3
xz5q1 1ybz8
9 Jun 23
Prospectus supplement
9:43pm
6-K
EX-1.1
yfbq8 d7wu
9 Jun 23
Current report (foreign)
9:39pm
424B3
a19ek4nr6se59tq6jq0v
8 Jun 23
Prospectus supplement
5:01pm
424B3
wmq3b
6 Jun 23
Prospectus supplement
4:20pm
424B3
7hhfcf 7ychmi130e
25 Apr 23
Prospectus supplement
8:14am
POS AM
i8ng2vpkn3anh0h vo
17 Apr 23
Prospectus update (post-effective amendment)
9:09am